Somatostatin analogs in the treatment of acromegaly

Endocrinology and Metabolism Clinics of North America

Volumn 21, Issue 3, 1992, Pages 737-752

  Lamberts, S W J ^a   Reubi, J C ^a   Krenning, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INSULIN; OCTREOTIDE; PROTIRELIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOHYPOPHYSIS; CONTROLLED STUDY; GALLSTONE FORMATION; GASTRITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0026713561     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0889-8529(18)30211-1     Document Type: Review

References (58)

1. Asa SL, Felix I, Singer W, et al: Effects of somatostatin on human pituitary somatotroph adenomas: An in vitro functional and morphologic study [abstract 93]. Endocr Soc 1990
2. Barakat S. Melmed S. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide Arch Intern Med 149 1989 1443
3. Barkan A.L. Kelch R.P. Hopwood N.J. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995 J Clin Endocrinol Metab 66 1988 16
4. Barkan A.L. Lloyd R.V. Chandler W.F. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate J Clin Endocrinol Metab 67 1988 1040
5. Bauer W. Brimer U. Doepfner W. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sei 31 1982 1133
6. Chanson P. Timsit J. Masquet C. Cardiovascular effects of the somatostatin analog octreotide in acromegaly Ann Intern Med 113 1990 921
7. Chiodini P.G. Cozzi R. Dallabonzana D. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine J Clin Endocrinol Metab 64 1987 447
8. Christensen S.E. Weeke J. Ørskov H. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients Clin Endocrinol 27 1987 297
9. Clemmons B.R. Van Wyk J.J. Ridgway E.C. Evaluation of acromegaly by radioimmunoassay of somatomedin-C N Engl J Med 301 1978 1138
10. Cobb W.E. Jackson I.M.D. Short-term recovery of visual field loss in acromegaly during treatment with a long-acting somatostatin analogue Am J Med 86 1989 496
11. Ducasse M.C.R. Tauber J.P. Tourre A. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995 J Clin Endocrinol Metab 65 1987 1042
12. Ezzat S. Ren S.-G. Braunstein G.D. Octreotide stimulates insulin-like growth factor binding protein-I (IGFB-I) levels in acromegaly J Clin Endocrinol Metab 73 1991 441
13. Halse J. Harris A.G. Kvistborg A. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: Clinical and biochemical effects J Clin Endocrinol Metab 70 1990 1254
14. Harris A.G. Prestele H. Herold K. Long-term efficacy of Sandostatin in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group Lamberts S.W.J. Sandostatin in the Treatment of Acromegaly 1988 Springer-Verlag New York 117
15. Ho K.Y. Weissberger A.J. Marbach P. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety Ann Intern Med 112 1990 173
16. Hofland L.J. van Koetsveld P.M. Verleun T.M. Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: Correlation with GH release Clin Endocrinol 30 1989 601
17. Hofland L.J. van Koetsveld P.M. van Vroonhoven C.C.J. Heterogeneity of growth hormones (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: Effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone J Clin Endocrinol Metab 68 1989 613
18. Hofland L.J. Velkeniers B. van Koetsveld P.M. The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH-secreting pituitary adenomas Clin Endocrinol 34 1991 5
19. Holly J.M.P. Cotterill R. Jemmott R.C. Interrelations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-I (IGFBP-I) and sex hormone-binding globulin in acromegaly Clin Endocrinol 34 1991 275
20. Ikuyama S. Nawata H. Kato K.I. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients J Clin Endocrinol Metab 62 1986 729
21. Ikuyama S. Nawata H. Kato K.I. Specific somatostatin receptors on human pituitary adenoma cells membranes J Clin Endocrinol Metab 6 1985 666
22. James R.A. Chatierjee S. White M.C. Continuous infusion of octreotide in acromegaly Lancet 1 1989 1083
23. Kelijman M. Williams T.C. Downs T.R. Comparison of the sensitivity of growth hormone secretion to Somatostatin in vivo and in vitro in acromegaly J Clin Endocrinol Metab 67 1988 958
24. Krenning E.P. Bakker W.H. Breeman W.A.P. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin Lancet 1 1989 242
25. Lamberts S.W.J. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors Endocr Rev 9 1988 417
26. Lamberts S.W.J. Sandostatin in the Treatment of Acromegaly 1988 Springer-Verlag New York 1
27. Lamberts S.W.J. Bakker W.H. Reubi J.-C. Somatostatin-receptor imaging in the localization of endocrine tumors N Engl J Med 323 1990 1246
28. Lamberts S.W.J. Hofland L.J. van Koetsveld P.M. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localization, and therapy J Clin Endocrinol Metab 71 1990 566
29. Lamberts S.W.J. Krenning E.P. Bakker W.H. Somatostatin receptor imaging in the diagnosis of pituitary and parasellar tumors Melmed S. Robbins R.J. Molecular and Clinical Advances in Pituitary Disorders 1991 Blackwell Scientific Boston 285
30. Lamberts S.W.J. Oosterom R. Neufeld M. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients J Clin Endocrinol Metab 60 1985 1161
31. Lamberts S.W.J. Uitterlinden P. del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years J Clin Endocrinol Metab 65 1987 703
32. Lamberts S.W.J. Uitterlinden P. Schuijff P.C. Therapy of acromegaly with Sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical “cure” Clin Endocrinol 29 1988 411
33. Lamberts S.W.J. Uitterlinden P. Verleun T. Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with Sandostatin (SMS 201-995) Eur J Clin Invest 17 1987 354
34. Lamberts S.W.J. Uitterlinden P. Verschoor L. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 N Engl J Med 313 1985 1576
35. Lamberts S.W.J. Verleun T. Oosterom R. The interrelationship between the effects of somatostatin and human pancreatic growth hormone-releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly J Clin Endocrinol Metab 58 1984 250
36. Lamberts S.W.J. Zweens M. Klijn J.G.M. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly Clin Endocrinol 25 1986 201
37. Lamberts S.W.J. Zweens M. Verschoor L. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs J Clin Endocrinol Metab 63 1986 16
38. Landolt A.M. Osterwalder V. Jantzer R. Preoperative treatment of acromegaly with SMS 201-995: Surgical and pathological observations Neuro Endocrinol Lett 7 1985 94
39. van Liessum P.A. Hopman W.P.M. Pieters G.F.F.M. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly J Clin Endocrinol Metab 69 1989 557
40. Losa M. Oeckler R. Schopohl J. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly J Neurosurg 70 1989 561
41. McKnight J.A. McCance D.R. Crothers J.G. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly Br Med J 299 1989 604
42. McKnight J.A. McCance D.R. Sheridant B. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly Clin Endocrinol 34 1991 119
43. Melmed S. Acromegaly N Engl J Med 322 1990 966
44. Melmed S. Braunstein G. Chang J. Pituitary tumors secreting growth hormone and prolactin Ann Intern Med 234 1986 1549
45. Moyse E. Le Dafniet M. Epelbaum J. Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas J Clin Endocrinol Metab 61 1985 98
46. Plöckinger U. Dienemann D. Quabbe H.-J. Gastrointestinal side-effects of octreotide during long term treatment of acromegaly J Clin Endocrinol Metab 71 1990 1658
47. del Pozo E. Neufeld M. Schlutter K. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration Acta Endocrinol 111 1986 433
48. Quabbe H.-J. Plöckinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly J Clin Endocrinol Metab 68 1989 873
49. Reubi J.-C. Heitz P.U. Landolt A.W. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: Evidence for different tumor subclasses J Clin Endocrinol Metab 65 1987 65
50. Reubi J.-C. Landolt A.M. High density of somatostatin receptors in pituitary tumors from acromegalic patients J Clin Endocrinol Metab 59 1984 1148
51. Reubi J.-C. Landolt A.M. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status J Clin Endocrinol Metab 68 1989 844
52. Sassolas G. Harris A.G. James-Deidier A. Long-term effect of incremental doses of the Somatostatin analog SMS 201-995 in 58 acromegalic patients J Clin Endocrinol Metab 71 1990 391
53. Serri O. Somma M. Comtois R. Acromegaly: Biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy J Clin Endocrinol Metab 61 1985 1185
54. Shi Y.F. Harris A.G. Zhu X.F. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients Clin Endocrinol 32 1990 695
55. Tauber J.P. Babin Th. Tauber M.T. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly J Clin Endocrinol Metab 68 1989 917
56. Thuesen L. Christensen S.E. Weeke J. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study Clin Endocrinol 30 1989 619
57. Wagenaar A.H. Harris A.G. van der Lely A.J. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly Acta Endocrinol (Copenh) 125 1991 637
58. Williams G. Ball J. Lawson R. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumors Br Med J 295 1987 247